- Home
- LEGH vs RVNC Comparison
LEGH vs RVNC Comparison
Compare LEGH & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- RVNC
- Stock Information
- Founded
- LEGH 2005
- RVNC 1999
- Country
- LEGH United States
- RVNC United States
- Employees
- LEGH N/A
- RVNC N/A
- Industry
- LEGH Homebuilding
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- RVNC Health Care
- Exchange
- LEGH Nasdaq
- RVNC Nasdaq
- Market Cap
- LEGH 682.3M
- RVNC 599.6M
- IPO Year
- LEGH 2018
- RVNC 2014
- Fundamental
- Price
- LEGH $27.25
- RVNC $5.78
- Analyst Decision
- LEGH Buy
- RVNC Buy
- Analyst Count
- LEGH 2
- RVNC 10
- Target Price
- LEGH $29.00
- RVNC $10.86
- AVG Volume (30 Days)
- LEGH 41.2K
- RVNC 1.6M
- Earning Date
- LEGH 11-12-2024
- RVNC 11-19-2024
- Dividend Yield
- LEGH N/A
- RVNC N/A
- EPS Growth
- LEGH N/A
- RVNC N/A
- EPS
- LEGH 2.18
- RVNC N/A
- Revenue
- LEGH $169,389,000.00
- RVNC $251,178,000.00
- Revenue This Year
- LEGH N/A
- RVNC $20.36
- Revenue Next Year
- LEGH $7.70
- RVNC $31.66
- P/E Ratio
- LEGH $12.61
- RVNC N/A
- Revenue Growth
- LEGH N/A
- RVNC 40.23
- 52 Week Low
- LEGH $18.00
- RVNC $2.30
- 52 Week High
- LEGH $29.31
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- LEGH 58.19
- RVNC 56.47
- Support Level
- LEGH $25.05
- RVNC $5.67
- Resistance Level
- LEGH $25.89
- RVNC $5.97
- Average True Range (ATR)
- LEGH 0.70
- RVNC 0.19
- MACD
- LEGH 0.20
- RVNC 0.06
- Stochastic Oscillator
- LEGH 84.78
- RVNC 78.01
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to customers to facilitate the sale of homes.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.